Xeris Biopharma (XERS) CEO holds 2,898,933 shares

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. (XERS) reported that its Chief Executive Officer and Chairman, Shannon John Patrick Jr, had 36,645 shares of common stock withheld on August 1, 2026. The shares were withheld by the company to satisfy income tax and withholding obligations upon net settlement of vested restricted stock units, not as an open-market sale. After this tax-withholding transaction, Patrick Jr directly holds 2,898,933 shares of XERS common stock.

Insider Trade Summary

Net Seller: 36,645 shares

Net Sell 1 txn

Insider Shannon John Patrick Jr

Role See Remarks

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	36,645	$8.08	$296K

Holdings After Transaction: Common Stock — 2,898,933 shares (Direct)

Footnotes (1)

1. F1. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of August 1, 2026.

Key Figures

Shares withheld for tax: 36,645 shares Per-share value for withholding: $8.08 per share Shares held after transaction: 2,898,933 shares

3 metrics

Shares withheld for tax 36,645 shares Common stock withheld on August 1, 2026 to satisfy tax and withholding obligations

Per-share value for withholding $8.08 per share Value used for the Code F tax-withholding disposition of 36,645 shares

Shares held after transaction 2,898,933 shares Total Xeris Biopharma common shares directly held by Shannon John Patrick Jr after the transaction

Key Terms

restricted stock units, net settlement, withheld by the Issuer

3 terms

restricted stock units financial

"in connection with the net settlement of restricted stock units vested"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

net settlement financial

"in connection with the net settlement of restricted stock units vested"

withheld by the Issuer financial

"Represents shares that have been withheld by the Issuer to satisfy"

FAQ

What insider transaction did XERS report for Shannon John Patrick Jr on August 1, 2026?

Xeris Biopharma Holdings, Inc. reported that 36,645 shares of XERS common stock were withheld on August 1, 2026 to cover income tax and withholding obligations related to the net settlement of vested restricted stock units held by CEO and Chairman Shannon John Patrick Jr.

Was the August 1, 2026 XERS insider transaction an open-market sale?

No. The Form 4 states the Code F transaction was a payment of tax liability by delivering or withholding securities. The 36,645 shares were withheld by Xeris Biopharma to satisfy tax and withholding obligations from vested restricted stock units, not sold on the open market.

How many XERS shares does Shannon John Patrick Jr hold after the reported transaction?

Following the August 1, 2026 tax-withholding transaction, Shannon John Patrick Jr directly holds 2,898,933 shares of Xeris Biopharma Holdings, Inc. common stock, as reported in the Form 4 under total shares following the transaction.

At what value were the withheld XERS shares recorded in the Form 4?

The 36,645 withheld shares of Xeris Biopharma common stock were reported at $8.08 per share in the Form 4, corresponding to the price used for the tax-withholding disposition related to vested restricted stock units.

What is the transaction code used in the August 1, 2026 XERS Form 4 filing?

The transaction is coded F, described as payment of tax liability by delivering or withholding securities. A footnote clarifies that the issuer withheld the shares to satisfy income tax and withholding obligations from net settlement of vested restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/21/2026 - 04:23 PM Accepted by SEC EDGAR 08/21/2026 - 04:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shannon John Patrick Jr

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO ILLINOIS 60607

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/01/2026		F		36,645(1)	D	$8.08	2,898,933	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of August 1, 2026.

Remarks:

Chief Executive Officer and Chairman of the Board

	/s/ Beth Hecht, Attorney-in-Fact	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)